Oncology trials

Brioche – Brain Re-Irradiation Or Chemotherapy: A Phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma.

LARCH

1.How do survival and quality of life outcomes compare between surgery and (chemo)radiotherapy in early and advanced laryngeal cancer?

2.How do the presenting features of laryngeal cancer influence oncological, functional and quality of life outcome?

PATHOS – A multicentre, randomised phase III study for HPV +ve Oropharyngeal cancer. Patients will have surgery then be randomised to an appropriate treatment deintensification strategy depending upon their pathological risk stratification. The trial is designed to look definitively at non-inferiority of overall survival and improvement in swallowing function and toxicity with treatment deintensification.

SCORE – Oropharyngeal cancer – Data collection

SIPSMART – Oropharyngeal cancer – SALT intervention/prehab

Moses – Evaluation of the role of tongue base MucOsectomy and Step sErial Sectioning in the management of the unknown primary squamous cell cancer in the head and neck.

Galaxies Lung-01 – A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer.

eVOLVE-Meso – A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma.

MK2870-007 – A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50%.

PA CAE – Prospective, Multi-Center, International Phase 2 Trial of the use of Ultrasonic Energy for Pulmonary Artery Branch Sealing during VATS Lobectomy and Cost Effectiveness Study.

Pacific-9 – A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.

Preserve 003 – Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors.

Stablemates – A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

No current active trials

Parable – Proton beam therapy in patients with breast cancer: evaluating early and late effects – test whether proton beam therapy (PBT)  can reduce mean heart dose to <1Gy in patients who would have incurred a mean heart dose of typically >3Gy from photon radiotherapy thereby contributing to around 2% or higher estimated absolute lifetime risk of radiation-induced late major cardiac event.

Also, comparing treatment toxicity and assessing patients’ acceptance of randomisation to PBT versus tailored photon RT.

ATNEC – To assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary treatment in terms of disease free survival (DFS) and results in reduced risk of lymphoedema at 5 years.

Sweet – Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET).

Roseta – Refining and Optimising a behavioural intervention to Support Endocrine Therapy Adherence

PACE- NODES – A phase III randomised trial of 5 fraction prostate SBRT (P-SBRT) versus 5 fraction prostate and pelvic nodal SBRT (PPN-SBRT) – patients with high risk prostate cancer.

Adapt-P – Impact of apalutamide in metastatic hormone sensitive prostate cancer patients, a multi-centre prospective observational study

Aurora – Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial.

Gusto – Gene expression subtypes of Urothelial cancer: Stratified Treatment and Oncological outcomes.

Oscar – Omics Approaches to Urological Cancer Diagnosis (‘OSCAR’).

Protector – Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal

Rango – Rare Neoplasms of Gynaecological Origin

MelMarT-II – Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma.

CVLP (Cancer Vaccine Launch Platform) – The aim of the CVLP is to investigate the basis for accelerated development of personalised cancer vaccine treatments, by testing a standardised, high quality, expanded pathway for tumour molecular analysis and sequencing, incorporating elements of the NHS Genomic Medicine Service. The initial phases of the CVLP will be a feasibility assessment to determine requirements and contributing factors for the development of a successful large scale sequencing platform to support trials of personalised cancer vaccines.

ICI Genetics – ICI Genetics: Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity.

Protect – RePROductive funcTion in tEenage and young adult Cancer paTients in the UK.

RDC Biomarker – Rapid Diagnostic Centre Biomarker Study.